Vertex Pharmaceuticals Incorporated
VRTX
$493.84
$1.370.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 5.05% | 4.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.05% | 4.77% | |||
| Cost of Revenue | -0.90% | -5.23% | |||
| Gross Profit | 10.08% | 15.02% | |||
| SG&A Expenses | -7.21% | -0.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.33% | -4.12% | |||
| Operating Income | 15.76% | 21.04% | |||
| Income Before Tax | -7.16% | 136.10% | |||
| Income Tax Expenses | 25.07% | -11.71% | |||
| Earnings from Continuing Operations | -12.67% | 129.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.67% | 129.09% | |||
| EBIT | 15.76% | 21.04% | |||
| EBITDA | 12.36% | 19.81% | |||
| EPS Basic | -12.50% | 129.10% | |||
| Normalized Basic EPS | 14.84% | 15.50% | |||
| EPS Diluted | -12.74% | 128.80% | |||
| Normalized Diluted EPS | 14.83% | 14.17% | |||
| Average Basic Shares Outstanding | -0.19% | -0.04% | |||
| Average Diluted Shares Outstanding | -0.19% | 1.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||